The field of immuno-oncology (IO) has fundamentally reshaped the landscape of cancer treatment. With the advent of immune checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies, researchers have discovered profound ways to harness the body's own immune system to target and destroy malignant cells. However, a significant bottleneck remains in the drug development pipeline: the...